<DOC>
	<DOCNO>NCT03055286</DOCNO>
	<brief_summary>This multicenter ( S. Korea/US ) , Phase Ib , open-label , dose-finding study ass safety , PK , PD , preliminary efficacy CWP232291 administer combination ara-C subject relapse refractory AML . Based poor prognosis relapsed/refractory AML , exploration alternative dos regimen evaluate approved Safety Review Committee ( SRC ) .</brief_summary>
	<brief_title>Clinical Study CWP232291 Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Understands willing sign inform consent form ( ICF ) prior initiation studyspecific procedure . 2 . 18 year age time consent . 3 . A pathologically confirm diagnosis AML World Health Organization ( WHO ) classification progress . 4 . Has fail ( refractory ) relapse 2 prior regimen , standard therapy option available . 5 . Subjects prior autologous allogeneic hematopoietic stem cell transplantation ( allo HSCT ) eligible . 6 . Adequate laboratory result include follow : Serum creatinine ≤ 2.0 mg/dL Total bilirubin ≤ 1.5 x upper limit institutional normal ( ULN ) , unless due Gilbert 's syndrome Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3 x ULN , unless due organ leukemic involvement 7 . Eastern Cooperative Oncology Group ( ECOG ) performance score 02 . 8 . The subject anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , biologic investigational agent least 14 day 5 half life , whichever great , prior enrollment exception hydroxyurea . All prior treatmentrelated nonhematologic toxicity must resolve ≤ grade 2 prior screening . 9 . Female subject childbearing potential ( ie , premenopausal surgically sterile ) must agree use effective contraception Day 1 28 day last dose study drug , negative serum urine pregnancy test within 2 week prior Day 1 . Sexually active male subject must also use effective contraception Day 1 90 day last dose study drug . 10 . Female subject must agree breastfeed screen throughout study period 45 day final study drug administration . Female subject must donate ovum start screen throughout study period 45 day final study drug administration . 11 . Male subject must donate sperm start screen throughout study period 90 day final study drug administration . 12 . Agree adhere study protocol requirement . 1 . Subject BCRABLpositive leukemia ( Chronic myeloid leukemia [ CML ] blast crisis ) . 2 . Subject diagnose acute promyelocytic leukemia ( APL ) . 3 . Subject AML secondary prior chemotherapy . 4 . Subject active clinically significant graft versus host disease ( GVHD ) treatment systemic corticosteroid GVHD ( except grade 1 skin GVHD ) . At least 3 month must elapse since completion allogeneic stem cell transplantation . 5 . Subject myocardial infarction within 6 month enrollment , heart failure ( New York Heart Association ( NYHA ) Class III IV ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , leave ventricular ejection fraction ( LVEF ) ≤ 40 % evidence acute ischemia active conduction system abnormality . 6 . Presence systemic fungal , bacterial , viral infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . 7 . Known tolerance allergy cytarabine . 8 . Active central nervous system ( CNS ) disease . 9 . Known positive status human immunodeficiency virus ( HIV ) and/or active hepatitis B C. 10 . Prior exposure CWP232291 . 11 . Pregnant breastfeed woman . 12 . Suitable imminent bone marrow transplant , within 4 week one . 13 . Major surgery within 4 week prior first study dose . 14 . Concurrent malignancy , unless patient diseasefree least five year follow curative intent therapy , follow exception : ( 1 ) adequately treat insitu carcinoma cervix ; ( 2 ) localize basal cell squamous cell carcinoma skin ; ( 3 ) previous malignancy confine treat locally ( surgery modality ) curative intent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>